ISSN: 2213-2600

Journal Home

The Lancet Respiratory Medicine Q1 Unclaimed

Elsevier Ltd United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

The Lancet Respiratory Medicine launched in March 2013 as the fourth Lancet specialty journal following in the footsteps of The Lancet Oncology, The Lancet Neurology, and The Lancet Infectious Diseases. The journal offers the same unique fast track experience offered by its sister journals for all authors of research papers that are selected for peer review, where articles can be published online within 8 weeks of submission. The Lancet Respiratory Medicine is indexed in PubMed, and has been approved for indexing and abstracting in SciSearch®, Journal Citation Reports, and Current Contents® by Thomson Reuters. It has an SJR impact factor of 7,965.

The Lancet Respiratory Medicine focuses its scope in these topics and keywords: pulmonary, chronic, randomised, fibrosis, idiopathic, obstructive, disease, diagnosisoncedaily, doubleblind, exacerbations, ...

Type: Journal

Type of Copyright:

Languages:

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Pulmonary and Respiratory Medicine (Q1)

Price

4598 €

Inmediate OA

0 €

Embargoed OA

0 €

Non OA

Metrics

7,965

SJR Impact factor

182

H Index

286

Total Docs (Last Year)

959

Total Docs (3 years)

5528

Total Refs

11689

Total Cites (3 years)

439

Citable Docs (3 years)

11.34

Cites/Doc (2 years)

19.33

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Lancet Respiratory Medicine,The Q1
Journal of Thoracic Oncology Q1
American Journal of Respiratory and Critical Care Medicine Q1
European Respiratory Journal Q1
Sleep Medicine Reviews Q1

Compare this journals

Aims and Scope

Best articles by citations

New antibiotic discovered for Gram-positive bacteria

Mastering breathlessness in patients with advanced respiratory disease

Space travel: medicine in extremes

Statistical methods for evaluating delirium in the ICU

Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data

Would pan-tuberculosis treatment regimens be cost-effective?

Improving outcomes in prolonged mechanical ventilation: a road map

Transcriptional phenotyping of fibrotic lung disease: a new gold standard?

South Africa confronts colliding respiratory epidemics

Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis

Respiratory infections in patients undergoing mechanical ventilation

Pollution control up in the air

SHOW MORE ARTICLES

Expression of concern

The nasal microbiota in infants with cystic fibrosis in the first year of life: a prospective cohort study

ARDS: promising insights for a challenging syndrome

Adenotonsillectomy improves asthma outcomes in children

Efficacy and safety of landiolol, an ultra-short-acting beta1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial

Selman Abraham Waksman

Why use the home sleep test?

Retraction and republication - Effect of early versus late or no tracheostomy on mortality of critically ill patients receiving mechanical ventilation: a systematic review and meta-analysis

Emerging respiratory infections: influenza, MERS-CoV, and extensively drug-resistant tuberculosis

Syria: the ongoing crisis

Ageing society and allergies challenge German health care

2015 American Thoracic Society International Conference